Transgenic Pig Islets Expressing HO-1 and TNFR1-Fc
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for islet transplantation in diabetes treatment face challenges due to immune rejection responses and oxidative stress, particularly in xenotransplantation using pig islets, where inflammatory cytokines like TNF-α induce rejection and cell damage, and existing technologies lack effective solutions for co-transfecting genes to inhibit these responses.
Innovation Solution
A transgenic pig is produced by introducing genes coding for human HO-1 protein and TNFR1-Fc fusion protein into somatic cells, which are then used in somatic cell nuclear transfer to create embryos, resulting in pigs that express these proteins, thereby reducing immune rejection and oxidative stress during transplantation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If islet xenotransplantation is performed using pig islets, then a sufficient quantity of donor islets can be obtained, but immune rejection responses and oxidative stress occur during transplantation
Solution Approach 1:
The patent applies preliminary anti-action by introducing HO-1 and TNFR1-Fc genes into pig islet cells before transplantation. HO-1 is an antioxidant enzyme that prevents oxidative stress, while TNFR1-Fc binds to TNF-α to inhibit inflammatory responses. These genetic modifications are performed in advance during cell culture, enabling the islet cells to resist immune rejection and oxidative stress when transplanted into diabetic patients.
Solution Approach 2:
The patent changes the biochemical parameters of pig islet cells by overexpressing HO-1 enzyme and TNFR1-Fc protein. This increases the antioxidant capacity and anti-inflammatory capability of the islet cells, transforming them from being susceptible to oxidative stress and immune rejection to being resistant, thereby enabling successful xenotransplantation.
2Adaptability or versatility
If multiple genes are co-transfected into somatic cells, then simultaneous expression of HO-1 and TNFR1-Fc is achieved, but the transfection process becomes complex
Solution Approach 1:
The patent merges the HO-1 gene and TNFR1-Fc gene into a single transfection system. Both genes are introduced into pig somatic cells simultaneously using co-transfection methods, allowing them to be expressed together in the same cells. This combined approach achieves the desired dual functionality while streamlining the genetic modification process.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The transgenic pigs exhibit reduced immune rejection and increased survival of islet cells by inhibiting TNF-α-mediated inflammatory responses and providing antioxidant protection, enhancing the success rate of islet xenotransplantation and organ transplantation.
Implementation Method 1
HO-1 (Heme oxygenase-1) is an enzyme that finally degrades heme into bilirubin and Fe2+, and is an antioxidant enzyme capable of cytoprotection via radical scavenging or apoptosis prevention
Implementation Method 2
TNF-α is a representative inflammatory cytokine, and a mediator that is mainly expressed in monocytes/macrophages and natural killer cells to induce inflammation
Data Source
AI summary
The present invention relates to a method for producing a transgenic pig in which immune rejection response is inhibited, and in which human HO-1 genes and TNFR1-Fe fusion genes are simultaneously expressed. The present invention also relates to a transgenic pig for organ transplantation, which is produced by the method, and in which immune rejection response is inhibited. The present invention also relates to a somatic-cell-donating cell strain for producing the transgenic pig, and to a method for producing organs, from the transgenic pig, in which the immune rejection response is inhibited.